Alliance Marks One of the Largest Biotech Drug Development Collaborations in China
As a part of the agreement, Innovent will lead the development and manufacturing for the
Lilly will contribute its cMet monoclonal antibody gene for possible treatment of non-small cell lung cancer. Separate from this collaboration, Lilly will continue the development of its cMet monoclonal antibody program outside of
Innovent will contribute its monoclonal antibody targeting protein CD-20 for investigation in hematologic malignancies. Innovent has received investigational new drug approval in
Chinato begin Phase I development of this potential therapy.
Innovent will contribute a pre-clinical immuno-oncology molecule for development in
China. The companies have agreed that Lilly will be responsible for development, manufacturing and commercialization of this molecule outside of China.
Lilly will also receive rights to develop and commercialize up to three pre-clinical bispecific immuno-oncology molecules outside of
Under the terms of the agreement, Innovent will receive a total upfront payment of
"We are pleased to collaborate with Innovent to develop potential therapies for those fighting cancer in
Lilly has a robust oncology pipeline that includes both small molecules and monoclonal antibodies, which are being studied to treat a wide range of cancers including breast, colorectal, liver and non-small cell lung.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
For more information, please visit www.innoventbio.com.
This press release contains forward-looking statements about the development and commercialization collaboration between Innovent Biologics and Lilly and reflects Lilly's current beliefs. However, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. There is no guarantee that the collaboration will yield successful results or that either company will achieve the anticipated benefits. For further discussion of these and other risks and uncertainties, see Lilly's most recent 10-K and 10-Q filings with the
Refer to: +1-317-277-6524; [email protected];
+86-10-59042059; [email protected];
+1-212-375-2694; [email protected];